DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2326-2335

  García Machorro, Jazmín ^a   López González, Moisés ^a   Barrios Rojas, Olivia ^a   Fernández Pomares, Cynthia ^a   Sandoval Montes, Claudia ^b   Santos Argumedo, Leopoldo ^a   Villegas Sepúlveda, Nicolás ^a   Gutiérrez Castañeda, Benito ^c   Cedillo Barrón, Leticia ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b Immunology Department National School of Biological Sciences National Polytechnic Institute Prolongación de Carpio y Plan de Ayala Col Plutarcoelías Calles   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Dengue enveloped protein Domain II and III; Immunization; Recombinant proteins

Indexed keywords

CR2 RECEPTOR BINDING DOMAIN DENGUE VIRUS 2 SUBUNIT FUSION PROTEIN; DENGUE VACCINE; EPITOPE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3D; COMPLEMENT RECEPTOR; HYBRID PROTEIN; PROTEIN BINDING; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DENGUE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; DENGUE VIRUS; DROSOPHILA MELANOGASTER; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; COMPLEMENT C3D; DENGUE VACCINES; DENGUE VIRUS; DROSOPHILA MELANOGASTER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PROTEIN BINDING; RECEPTORS, COMPLEMENT; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84887427629     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25673     Document Type: Article

References (50)

1. PAHO Dengue regional information: Number of cases. http://new.paho.org/ hq/index. php?option=com-content&task=view&id=264&Ite mid=363. PAHO (2011).
2. AñezG, Morales-Betoulle ME, Rios M. Circulation of different lineages of dengue virus type 2 in Central America, their evolutionary time-scale and selection pressure analysis.PLoS One2011; 6:e27459; PMID: 22076162; http://dx.doi.org/10.1371/journal. p on e.0 0 2 7459
3. Durbin AP, Whitehead SS. Next-generation dengue vaccines: novel strategies currently under develop-ment.Viruses2011; 3: 1800-14; PMID: 22069516; http://dx.doi.org/10.3390/v3101800
4. Heinz FX, Stiasny K. Flaviviruses and flavivirus vac-cines.Vaccine2012; 30: 4301-6; PMID: 22682286; http://dx.doi.org/10.1016/j.vaccine.2011.09.114
5. Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, et al.Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.Virology1992; 187: 480-91; PMID: 1372140; http://dx.doi.org/10. 1016/0042-6822(92)90450-4
6. Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.J Virol2002; 76: 13097-100; PMID: 12438639; http://dx.doi.org/10.1128/JVI.76.24.13097-13100.2002 (Pubitemid 35386997)
7. Heinz FX, Stiasny K. Flaviviruses and their anti-genic structure.J Clin Virol2012; 55: 289-95; PMID: 22999801
8. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al.The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.Cell Host Microbe2010; 8: 271-83; PMID: 20833378; http://dx.doi.org/10.1016/j.chom. 2010.08.007
9. Goncalvez AP, Purcell RH, Lai CJ. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.J Virol2004; 78: 12919-28; PMID: 15542644; http://dx.doi.org/10.1128/JVI.78.23.12919-12928.2004 (Pubitemid 39507800)
10. Gollins SW, Porterfield JS. A new mechanism for the neutralization of enveloped viruses by antiviral antibody.Nature1986; 321: 244-6; PMID: 3713806; http://dx.doi.org/10.1038/321244a0 (Pubitemid 16016417)
11. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glyco-protein are the most efficient blockers of virus adsorption to Vero cells.J Virol2001; 75: 7769-73; PMID: 114 62 0 53; http://dx.doi.org/ 10.1128/JVI.75.16.7769-7773.2001 (Pubitemid 32738039)
12. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al.Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.Cell2002; 108: 717-25; PMID: 11893341; http://dx.doi.org/10.1016/S0092-8674(02)00660-8 (Pubitemid 34241430)
13. Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein.J Virol2005; 79: 1223-31; PMID: 15613349; http://dx.doi.org/10.1128/JVI.79.2.1223-1231.2005 (Pubitemid 40053904)
14. Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, et al.Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient.Virol J2010; 7: 28; PMID: 20132551; ht tp://dx.doi.org/10.1186/1743-422X-7-28
15. Amorim JH, Diniz MO, Cariri FA, Rodrigues JF, Bizerra RS, Gonçalves AJ, et al.Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant.Vaccine2012; 30: 837-45; PMID: 2 2178517; http://dx.doi.org/10.1016/j. vaccine.2011.12.034
16. Costa SM, Paes MV, Barreto DF, Pinhão AT, Bart h OM, Queiroz JL, et al.Protection against dengue type 2 virus induced in mice immunized with a DNA plas-mid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine2006; 24: 195-205; PMID: 16122850; http://dx.doi.org/10.1016/j.vaccine.2005.07.059 (Pubitemid 41753007)
17. Lu H, Xu XF, Gao N, Fan DY, Wang J, An J. Preliminary evaluation of DNA vaccine candidates encoding den-gue-2 pr M/E and NS1: their immunity and protective efficacy in mice.MolImmunol2013; 54: 109-14; PMID: 23270684
18. Zhang F, Ma W, Zhang L, Aasa-Chapman M, Zhang H. Expression of particulate-form of Japanese encephalitis virus envelope protein in a stably transfected Drosophila cell line.Virol J2007; 4: 17; PMID: 17324254; http://dx.doi. or g/10.118 6/174 3 - 4 2 2 X- 4-17
19. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, et al.Development of a recom-binant tetravalent dengue virus vaccine: immuno-genicity and efficacy studies in mice and monkeys. Vaccine2010; 28: 2705-15; PMID: 20097152; http://dx.doi.org/10.1016/j.vaccine.2010.01.022
20. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.Vaccine2011; 29: 7267-75; PMID: 21777637; http://dx.doi.org/10. 1016/j. vaccine.2011.07.021
21. Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.Vaccine2010; 28: 8085-94; PMID: 20959154; http://dx.doi.org/10.1016/j.vaccine.2010.10.004
22. Hermida L, Rodríguez R, Lazo L, Silva R, Zulueta A, Chinea G, et al.A dengue-2 Envelope fragment inserted within the structure of the P64k menin-gococcal protein carrier enables a functional immune response against the virus in mice.J Virol Methods2004; 115: 41-9; PMID: 14656459; http://dx.doi.org/10.1016/j.jviromet.2003.09.024 (Pubitemid 37500961)
23. Srivastava AK, Putnak JR, Warren RL, Hoke CHJr. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine1995; 13: 1251-8; PMID: 8578812; http://dx.doi.org/10.1016/0264-410X(94)00059-V
24. Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, et al.A consensus envelope protein domain III can induce neutralizing antibody responses against sero-type 2 of dengue virus in non-human primates.Arch V i r o l 2 01 3; 15 8: 152 3 - 31; PMID: 23456422; http://d x.doi. or g/10.10 07/s 0 0 705 - 013-1639-1
25. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.Annu Rev Immunol1995; 13: 127-49; PMID: 7542009; ht t p://d x.doi. or g/10.114 6/a nnu r e v. iy.13.040195.001015
26. Carroll MC, Isenman DE. Regulation of humoral immunity by complement.Immunity2012; 37: 199-207; PMID: 2 2 9 21118; http://dx.doi.org/10. 1016/j. immuni.2012.08.002
27. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.AIDS Res Hum Retroviruses2001; 17: 82 9-35; PMID: 114 2 91 2 4; http://dx.doi.org/10.1089/088922201750252025 (Pubitemid 32692398)
28. Bower JF, Ross TM. A minimum CR2 binding domain of C3d enhances immunity following vaccination.Adv Exp Med Biol2006; 586: 249-64; PMID: 16893077; http://dx.doi.org/10.1007/0-387-34134-X-17
29. Liu D, Wang J, Niu ZX. Contribution of Chinese Pekin duck complement component C3d-P29 repeats to enhancement of Th2-biased immune responses against NDV F gene induced by DNA immuni-zation.Immunopharmacol Immunotoxicol2010; 32: 297-306; PMID: 20148704; http://dx.doi.org/10.3109/08923970903311802
30. Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, et al.Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J2010; 7: 95; PMID: 20462412; http://dx.doi. or g/10.118 6/174 3 - 4 2 2 X-7-9 5
31. Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res2003; 59: 141-75; PMID: 14696329; http://dx.doi.org/10.1016/S0065-3527(03) 59005-4 (Pubitemid 137640952)
32. Chen Y, Maguire T, Marks RM. Demonstration of binding of dengue virus envelope protein to target cells.J Virol1996; 70: 8765-72; PMID: 8971005 (Pubitemid 26378460)
33. Chen MC, Lin CF, Lei HY, Lin SC, Liu HS, Yeh TM, et al.Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency.J Immunol2009; 183: 1797-803; PMID: 19592650; http://dx.doi.org/10.4049/jimmunol.0800672
34. Mellado-Sánchez G, García-Machorro J, Sandoval-Montes C, Gutiérrez-Castañeda B, Rojo-Domínguez A, García-Cordero J, et al.A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model. Arch Virol2010; 155: 847-56; PMID: 20390312; http://dx.doi.org/10.1007/s00705-010-0652-x
35. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.Vaccine2011; 29: 7229-41; PMID: 21745521; http://dx.doi.org/10.1016/j. vaccine.2011.06.094
36. Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al.An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.Vaccine2005; 23: 4442-52; PMID: 16005749; http://dx.doi.org/10.1016/j.vaccine.2005.03.042 (Pubitemid 40991230)
37. Zheng Q, Fan D, Gao N, Chen H, Wang J, Ming Y, et al.Evaluation of a DNA vaccine candidate expressing pr M-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and pro-tection.Vaccine2011; 29: 763-71; PMID: 21095256; http://dx.doi.org/10.1016/j.vaccine.2010.11.014
38. Hughes HR, Crill WD, Chang GJ. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J2012; 9: 115; PMID: 22709350; http://dx.doi.org/10.1186/1743 - 422 X-9-115
39. Coconi-Linares N, Ortega-Dávila E, López-González M, García-Machorro J, García-Cordero J, Steinman RM, Cedillo-Barrón L, Gómez-Lim MA. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice. Vaccine 2013; 31: 2366-71; PMID: 23499580; http://dx.doi.org/10.1016/j. vaccine.2013.03.009
40. Augusto EF, Moraes AM, Piccoli RA, Barral MF, Suazo CA, Tonso A, et al.Nomenclature and guideline to express the amount of a membrane protein synthesized in animal cells in view of bioprocess optimization and production monitoring.Biologicals2010; 38: 105-12; PMID: 19699109; http://dx.doi.org/10. 1016/j.biologicals.2009.07.005
41. Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS, et al.Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement.J Immunol2005; 175: 8011-23; PMID: 16339538 (Pubitemid 41798363)
42. Haspel N, Ricklin D, Geisbrecht BV, Kavraki LE, Lambris JD. Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d.Protein Sci2008; 17: 1894-906; PMID: 18687868; http://dx.doi.org/10.1110/ps.036624.108
43. Gor DO, Ding X, Li Q, Greenspan NS. Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol Lett2006; 102: 38-49; PMID: 16105692; http://dx.doi.org/10.1016/j.imlet.2005.06.020 (Pubitemid 41606038)
44. Suradhat S, Braun RP, Lewis PJ, Babiuk LA, van Drunen Littel-van den Hurk S, Griebel PJ, et al.Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immu-nization.Vet ImmunolImmunopathol2001; 83: 79-92; PMID: 11604163; http://dx.doi.org/10.1016/S0165-2427(01)00369-5 (Pubitemid 32927187)
45. da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nuñez NV, Colpitts TM, van der Ende-Metselaar H, Fikrig E, et al.Antibodies against the envelope gly-coprotein promote infectivity of immature dengue virus serotype 2.PLoS One2012; 7:e29957; PMID: 22431958; http://dx.doi.org/10.1371/journal. pone.0029957
46. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al.Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.Proc NatlAcad Sci U S A2012; 109: 7439-44; PMID: 22499787; http://dx.doi.org/10.1073/pnas.1200566109
47. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, et al.Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.J Virol2006; 80: 12149-59; PMID: 17035317; http://dx.doi.org/10.1128/JVI.01732-06 (Pubitemid 44904366)
48. Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, et al.Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.J Virol2013; 87: 52-66; PMID: 23077306; http://dx.doi.org/10.1128/JVI.02273-12
49. Bustos-Arriaga J, García-Machorro J, León-Juárez M, García-Cordero J, Santos-Argumedo L, Flores-Romo L, et al.Activation of the innate immune response against DENV in normal non-transformed human fibroblasts.PLo SNegl Trop Dis2011; 5:e1420; PMID: 22206025; http://dx.doi.org/10.1371/jour-nal.pntd.0001420
50. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization.J Clin Microbiol1985; 22: 250-4; PMID: 4031038 (Pubitemid 15006964)